| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/24/2013 | CN101979093B Composition comprising polypeptide-drug substance and other poorly absorbed active ingredient and its use |
| 04/24/2013 | CN101972385B Method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines |
| 04/24/2013 | CN101945875B Azaindolizines and methods of use |
| 04/24/2013 | CN101879137B Method for preparing stealth liposome |
| 04/24/2013 | CN101787013B Novel lipoamide derivatives and preparation method and pharmaceutical application thereof |
| 04/24/2013 | CN101684159B Protein derivatives of human granzyme B, and use thereof in targeted therapy on adenocarcinoma |
| 04/24/2013 | CN101643789B RNA interference mediating small RNA molecules |
| 04/24/2013 | CN101642451B New application of amiodarone and derivatives thereof |
| 04/24/2013 | CN101641115B Epha3 antibodies for the treatment of solid tumors |
| 04/24/2013 | CN101611036B Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 04/24/2013 | CN101597321B LHRH antagonist with long-acting low-histamine release side effect |
| 04/24/2013 | CN101583280B Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents |
| 04/24/2013 | CN101537015B Application of carbon nano-tubes in immunity accelerators for preparing anti-tumor immunotherapy medicaments |
| 04/24/2013 | CN101535312B 吡咯并三嗪激酶抑制剂 Pyrrolotriazine kinase inhibitors |
| 04/24/2013 | CN101516374B Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
| 04/24/2013 | CN101501049B Aminophosphoric acid ester derivative and S1P receptor modulator containing the same as active ingredient |
| 04/24/2013 | CN101410413B Anti-EPHRINB2 antiboies and methods using same |
| 04/24/2013 | CN101355936B Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
| 04/24/2013 | CN101160324B Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| 04/24/2013 | CN101155582B Compositions and methods for treating neoplastic diseases |
| 04/23/2013 | US8426588 Phenylalanine derivatives |
| 04/23/2013 | US8426585 Compounds comprising a spiro-ring |
| 04/23/2013 | US8426428 EGFR kinase knockdown via electrophilically enhanced inhibitors |
| 04/23/2013 | US8426427 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 04/23/2013 | US8426418 Method to treat melanoma in BRAF inhibitor-resistant subjects |
| 04/23/2013 | US8426402 Benzodiazepine derivatives |
| 04/23/2013 | US8426205 Method for selective electrofusion of at least two fusion partners having cell-like membranes |
| 04/23/2013 | US8426198 In vitro differentiated cell and human embryonic stem cell population |
| 04/23/2013 | US8426147 RORS as modifiers of the p21 pathway and methods of use |
| 04/23/2013 | US8425939 Remedy |
| 04/23/2013 | US8425917 Mutant forms of EtxB and CtxB and their use as carriers |
| 04/23/2013 | US8425912 Immunoconjugates with an intracellularly-cleavable linkage |
| 04/23/2013 | US8425911 Methods of treating secondary bone tumors with antibodies against PDGFR alpha |
| 04/23/2013 | US8425908 Treatment with anti-ErbB2 antibodies |
| 04/23/2013 | US8425903 Methods of treatment by administering antibodies to notch receptors |
| 04/23/2013 | US8425896 Treatment of tumors with recombinant interferon alpha |
| 04/23/2013 | CA2709202C Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| 04/23/2013 | CA2588396C 17,20(e)-dehydro vitamin d analogs and their uses |
| 04/23/2013 | CA2557989C Sulfated oligosaccharide derivatives |
| 04/23/2013 | CA2556069C Compounds having antitumor activity |
| 04/23/2013 | CA2555712C Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |
| 04/23/2013 | CA2546189C Inhibitors of the mutant form of kit |
| 04/23/2013 | CA2542650C Bridged ring structures as pharmaceutical agents |
| 04/23/2013 | CA2535185C 2-methylene-19-nor-vitamin d2 compounds |
| 04/23/2013 | CA2515761C Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 04/23/2013 | CA2494764C Treatment of melanoma by reduction in clusterin levels |
| 04/23/2013 | CA2475102C Stabilized synthetic immunogen delivery systems |
| 04/23/2013 | CA2451637C Liver engrafting cells, assays, and uses thereof |
| 04/23/2013 | CA2436245C Medicament for protection in radiotherapy |
| 04/23/2013 | CA2416761C Method for screening peptides for use in immunotherapy |
| 04/18/2013 | WO2013056248A2 Treatment of breast cancer with companion diagnostic |
| 04/18/2013 | WO2013056216A1 Micrornas and methods of using same |
| 04/18/2013 | WO2013056183A1 Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
| 04/18/2013 | WO2013056105A2 INHIBITION OF SPINAL MAMMALIAN TARGET OF RAPAMYCIN (mTOR) REDUCES CANCER PAIN, OPIOID TOLERANCE, AND HYPERALGESIA |
| 04/18/2013 | WO2013056067A1 Compounds for use in the treatment of basal cell carcinoma |
| 04/18/2013 | WO2013056015A1 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| 04/18/2013 | WO2013055987A1 Pyrrolobenzodiazepines and conjugates thereof |
| 04/18/2013 | WO2013055949A2 Pyrazol-3-ones that activate pro-apoptotic bax |
| 04/18/2013 | WO2013055897A1 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | WO2013055793A1 Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| 04/18/2013 | WO2013055771A1 Thioxothiazolidinone derivatives useful as inhibitors of tdp1 |
| 04/18/2013 | WO2013054998A1 Novel chalcone derivative and anticancer composition comprising same as active ingredient |
| 04/18/2013 | WO2013054331A1 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| 04/18/2013 | WO2013054204A2 A process for making an intermediate of cabazitaxel |
| 04/18/2013 | WO2013054185A1 Pyrimidine and pyridine derivatives useful in therapy |
| 04/18/2013 | WO2013053983A1 Protein kinase inhibitors |
| 04/18/2013 | WO2013053873A1 Pyrrolobenzodiazepines |
| 04/18/2013 | WO2013053872A1 Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| 04/18/2013 | WO2013053871A1 Pyrrolobenzodiazepines |
| 04/18/2013 | WO2013053836A1 Composition comprising anaerobically cultivated human intestinal microbiota |
| 04/18/2013 | WO2013053775A1 Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| 04/18/2013 | WO2013053694A1 Monoclonal anti-idiotype antibody ganglidiomab |
| 04/18/2013 | WO2013053273A1 Imidazo quinoline derivative and medicinal salt thereof, preparation method thereof and use in medicine thereof |
| 04/18/2013 | WO2013053206A1 Quinazoline derivatives as kinases inhibitors and methods of use thereof |
| 04/18/2013 | WO2013053080A1 Anti-tumour fusion protein and coding gene and use thereof |
| 04/18/2013 | WO2013053051A1 Indazole compounds as kinase inhibitors and method of treating cancer with same |
| 04/18/2013 | WO2013053045A1 Heterocyclic molecules as apoptosis inducers |
| 04/18/2013 | WO2013023043A3 Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy |
| 04/18/2013 | WO2013022991A3 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
| 04/18/2013 | WO2013022927A3 Treatment of uterine leiomyomata |
| 04/18/2013 | US20130096180 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same |
| 04/18/2013 | US20130096176 Modulation of insulin like growth factor i receptor expression |
| 04/18/2013 | US20130096166 Camalexin as a treatment for prostate cancer |
| 04/18/2013 | US20130096157 Quinoline derivatives and uses of the same |
| 04/18/2013 | US20130096144 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| 04/18/2013 | US20130096128 Pyrazole compounds useful as protein kinase inhibitors |
| 04/18/2013 | US20130096121 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | US20130096120 Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases |
| 04/18/2013 | US20130096116 Treatment of pharmacological-induced hypochlorhydria |
| 04/18/2013 | US20130096113 Heterocyclic compounds and methods of use thereof |
| 04/18/2013 | US20130096090 Transition metal complexes of amino acids and related ligands and their use as catalysts, anti-microbials, and anti-cancer agents |
| 04/18/2013 | US20130095569 Pregnancy-associated plasma protein-a2 (papp-a2) polynucleotides |
| 04/18/2013 | US20130095549 Tweak receptor |
| 04/18/2013 | US20130095482 Methods of detecting pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/18/2013 | US20130095475 Genes from the 20q13 amplicon and their uses |
| 04/18/2013 | US20130095198 Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process |
| 04/18/2013 | US20130095194 Use of inhaled nitrous oxide or xenon for preventing neuropathic pain caused by cancer chemotherapy |
| 04/18/2013 | US20130095176 Controlled release drug delivery compostion |
| 04/18/2013 | US20130095172 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| 04/18/2013 | US20130095106 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |